Hájková, R <br/><br/>
Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.  [electronic resource] 

 -  Folia biologica  1999 
 - 227-31 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0015-5500 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>CD4-Positive T-Lymphocytes--immunology<br/>Cancer Vaccines--therapeutic use<br/>Carcinoma--immunology<br/>Combined Modality Therapy<br/>Cross Reactions<br/>Cytotoxicity Tests, Immunologic<br/>DNA, Complementary--genetics<br/>Disease Progression<br/>Genetic Therapy<br/>Immunotherapy, Active<br/>Interleukin-2--genetics<br/>Killer Cells, Natural--immunology<br/>Mice<br/>Mice, Inbred C57BL<br/>Neoplasm Recurrence, Local--prevention & control<br/>Neoplasm Transplantation<br/>Neoplasm, Residual<br/>Recombinant Fusion Proteins--physiology<br/>Sarcoma, Experimental--metabolism<br/>Spleen--immunology<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Transfection<br/>Tumor Cells, Cultured--immunology<br/>Vaccination